AstraZeneca Pharma India has initiated the commercial launch of XIGDUO XR, a product of AstraZeneca Group and has been approved in 61 countries to date including US, EU and Japan.
XIGDUO XR is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus when treatment with both dapagliflozin and metformin is appropriate.
Earlier, the company had announced that FDC of Dapagliflozin + Metformin Hydrochloride film coated tablets (XIGDUO XR) was expected to be launched in India in Q4 of FY 2017-18.
AstraZeneca Pharma India is a global biopharmaceutical company. The company is engaged in the discovery, development and commercialization of medicines for core areas of healthcare, including cardiovascular/metabolic disease, cancer and respiratory, inflammatory and autoimmune disease. The company operates through two segments Healthcare and Clinical Trial.
